Latest news
XENE Maintained by RBC Capital -- Price Target Lowered to $81.00 - GuruFocusGuruFocus · Fri, 07 Aug 2026 23:00:31 GMTWedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating - MoomooMoomoo · Fri, 07 Aug 2026 20:05:42 GMTXenon Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 20:04:17 GMTFDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE) - simplywall.stsimplywall.st · Fri, 07 Aug 2026 18:52:11 GMTXenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 18:03:22 GMTXENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 14:12:00 GMTRBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 13:47:20 GMTXENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63 - BitgetBitget · Fri, 07 Aug 2026 11:56:41 GMT